Correct diagnosis of stroke and its subtypes is pivotal in early stages for optimum treatment.
Aims
The aim of this systematic review and meta-analysis is to summarize the published evidence on the potential of blood biomarkers in the diagnosis and differentiation of stroke subtypes.
Methods
A literature search was conducted for papers published until 20 April 2020 in PubMed, EMBASE, Cochrane Library, TRIP, and Google Scholar databases to search for eligible studies investigating the role of blood biomarkers in diagnosing stroke. Quality assessment was done using modified Quality Assessment of Diagnostic Accuracy Studies questionnaire. Pooled standardized mean difference and 95% confidence intervals were calculated. Presence of heterogeneity among the included studies was investigated using the Cochran's Q statistic and I2 metric tests. If I2 was < 50% then a fixed-effect model was applied else a random-effect model was applied. Risk of bias was assessed using funnel plots and between-study heterogeneity was assessed using meta-regression and sensitivity analyses. Entire statistical analysis was conducted in STATA version 13.0.
Results
A total of 40 studies including patients with 5001 ischemic strokes, 756 intracerebral hemorrhage, 554 stroke mimics, and 1774 healthy control subjects analyzing 25 biomarkers (within 24 h after symptoms onset/after the event) were included in our meta-analysis; 67.5% of studies had moderate evidence of quality. Brain natriuretic peptide, matrix metalloproteinase-9, and D-dimer significantly differentiated ischemic stroke from intracerebral hemorrhage, stroke mimics, and health control subjects (p < 0.05). Glial fibrillary acidic protein successfully differentiated ischemic stroke from intracerebral hemorrhage (standardized mean difference −1.04; 95% confidence interval −1.46 to −0.63) within 6 h. No studies were found to conduct a meta-analysis of blood biomarkers differentiating transient ischemic attack from healthy controls and stroke mimics.
Conclusion
This meta-analysis highlights the potential of brain natriuretic peptide, matrix metalloproteinase-9, D-dimer, and glial fibrillary acidic protein as diagnostic biomarkers for stroke within 24 h. Results of our meta-analysis might serve as a platform for conducting further targeted proteomics studies and phase-III clinical trials.
ChalelaJAKidwellCSNentwichLM, et al.Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet2007; 369: 293–298.
2.
RoseKMRosamondWDHustonSLMurphyCVTegelerCH. Predictors of time from hospital arrival to initial brain-imaging among suspected stroke patients: the North Carolina Collaborative Stroke Registry. Stroke2008; 39: 3262–3267.
3.
NogueiraRGJadhavAPHaussenDC, et al.Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med2018; 378: 11–21.
4.
AlbersGWMarksMPKempS, et al.Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med2018; 378: 708–718.
5.
MoherDShamseerLClarkeM, et al.Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev2015; 4: 1.
6.
WhiteleyWTsengM-CSandercockP. Blood biomarkers in the diagnosis of ischemic stroke: a systematic review. Stroke2008; 39: 2902–2909.
7.
BeggCBMazumdarM. Operating characteristics of a rank correlation test for publication bias. Biometrics1994; 50: 088–101.
8.
EggerMDavey SmithGSchneiderMMinderC. Bias in meta-analysis detected by a simple, graphical test. BMJ1997; 315: 629–634.
9.
WanXWangWLiuJTongT. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol2014; 14: 135.
10.
DerSimonianRLairdN. Meta-analysis in clinical trials. Control Clin Trials1986; 7: 177–188.
11.
LugerSWitschJDietzA, et al.Glial fibrillary acidic protein serum levels distinguish between intracerebral hemorrhage and cerebral ischemia in the early phase of stroke. Clin Chem2017; 63: 377–385.
12.
RozanskiMWaldschmidtCKunzA, et al.Glial fibrillary acidic protein for prehospital diagnosis of intracerebral hemorrhage. Cerebrovasc Dis Basel Switz2017; 43: 76–81.
13.
FoerchCNiessnerMBackT, et al.Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. Clin Chem2012; 58: 237–245.
14.
KnauerCKnauerKMüllerS, et al.A biochemical marker panel in MRI-proven hyperacute ischemic stroke—a prospective study. BMC Neurol2012; 12: 14.
15.
DvorakFHabererISitzerMFoerchC. Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke. Cerebrovasc Dis2009; 27: 37–41.
16.
FoerchCCurdtIYanB, et al.Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J Neurol Neurosurg Psychiat2006; 77: 181–184.
17.
Horstmann S, Kalb P, Koziol J, Gardner H and Wagner S. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 2003; 34: 2165–2170.
18.
LugerSJægerHSDixonJ, et al.Diagnostic accuracy of glial fibrillary acidic protein and ubiquitin carboxy-terminal hydrolase-L1 serum concentrations for differentiating acute intracerebral hemorrhage from ischemic stroke [published online ahead of print, 2020 Feb 24]. Neurocrit Care2020. DOI: 10.1007/s12028-020-00931-5.
19.
BustamanteALópez-CancioEPichS, et al.Blood biomarkers for the early diagnosis of stroke: the stroke-chip study. Stroke2017; 48: 2419–2425.
20.
LlombartVGarcía-BerrocosoTBustamanteA, et al.Plasmatic retinol-binding protein 4 and glial fibrillary acidic protein as biomarkers to differentiate ischemic stroke and intracerebral hemorrhage. J Neurochem2016; 136: 416–424.
21.
MontanerJMendiorozMDelgadoP, et al.Differentiating ischemic from hemorrhagic stroke using plasma biomarkers: the S100B/RAGE pathway. J Proteomics2012; 75: 4758–4765.
22.
MontanerJMendiorozMRibóM, et al.A panel of biomarkers including caspase-3 and D-dimer may differentiate acute stroke from stroke-mimicking conditions in the emergency department. J Intern Med2011; 270: 166–174.
23.
CastellanosMLeiraRSerenaJ, et al.Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke2003; 34: 40–46.
24.
CastellanosMCastilloJGarcíaMM, et al.Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke2002; 33: 982–987.
25.
AltèsAAbellánMTMateoJAvilaAMarti-VilaltaJLFontcubertaJ. Hemostatic disturbances in acute ischemic stroke: a study of 86 patients. Acta Haematol1995; 94: 10–15.
26.
RenCKobeissyFAlawiehA, et al.Assessment of serum UCH-L1 and GFAP in acute stroke patients. Sci Rep2016; 6: 24588.
27.
ZhouSBaoJWangYPanS. S100β as a biomarker for differential diagnosis of intracerebral hemorrhage and ischemic stroke. Neurol Res2016; 38: 327–332.
28.
XiongLYangYZhangMXuW. The use of serum glial fibrillary acidic protein test as a promising tool for intracerebral hemorrhage diagnosis in Chinese patients and prediction of the short-term functional outcomes. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol2015; 36: 2081–2087.
29.
MengRLiZ-YJiXWangX. Antithrombin III associated with fibrinogen predicts the risk of cerebral ischemic stroke. Clin Neurol Neurosurg2011; 113: 380–386.
30.
AnS-AKimJKimO-J, et al.Limited clinical value of multiple blood markers in the diagnosis of ischemic stroke. Clin Biochem2013; 46: 710–715.
31.
ParkS-YKimM-HKimO-J, et al.Plasma heart-type fatty acid binding protein level in acute ischemic stroke: comparative analysis with plasma S100B level for diagnosis of stroke and prediction of long-term clinical outcome. Clin Neurol Neurosurg2013; 115: 405–410.
32.
KimMHKangSYKimMCLeeWI. Plasma biomarkers in the diagnosis of acute ischemic stroke. Ann Clin Lab Sci2010; 40: 336–341.
33.
HeoJHKimSHLeeKYKimEHChuCKNamJM. Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure. Stroke2003; 34: e48–e50.
34.
LuciveroVPronteraMMezzapesaDM, et al.Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke. Neurol Sci2007; 28: 165–170.
35.
MazzottaGSarchielliPCasoV, et al.Different cytokine levels in thrombolysis patients as predictors for clinical outcome. Eur J Neurol2004; 11: 377–381.
36.
AgenoWFinazziSSteidlL, et al.Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes. Arch Intern Med2002; 162: 2589–2593.
37.
PeriniFMorraMAlecciMTosoV. Temporal profile of serum anti-inflammatory and pro-inflammatory interleukins in acute ischemic stroke patients. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol2001; 22: 289–296.
38.
BhatiaRWarrierABaliPSisodiaPGuptaAVishnubhatlaSVivekanandhanSSrivastavaVPPrasadK. Role of blood biomarkers in differentiating ischemic stroke and intracerebral hemorrhage. Neurology2018, 90: 2.pp. 230. .
39.
RajeshwarKKaulSAl-HazzaniA, et al.C-reactive protein and nitric oxide levels in ischemic stroke and its subtypes: correlation with clinical outcome. Inflammation2012; 35: 978–984.
40.
KatsanosAHMakrisKStefaniD, et al.Plasma glial fibrillary acidic protein in the differential diagnosis of intracerebral hemorrhage. Stroke2017; 48: 2586–2588.
41.
KavalciCGenchallacHDurukanPCevikY. Value of biomarker-based diagnostic test in differential diagnosis of hemorrhagic-ischemic stroke. Bratisl Lek Listy2011; 112: 398–401.
42.
StejskalDSporovaLSvestakMKarpisekM. Determination of serum visinin like protein-1 and its potential for the diagnosis of brain injury due to the stroke: a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub2011; 155: 263–268.
43.
GlickmanSWPhillipsSAnstromKJLaskowitzDTCairnsCB. Discriminative capacity of biomarkers for acute stroke in the emergency department. J Emerg Med2011; 41: 333–339.
UndénJStrandbergKMalmJCampbell E, Rosengren L, Stenflo J, Norrving B, Romner B, Lindgren A, AndsbergG. Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation. J Neurol2009; 256: 72–77.
46.
Shenhar-TsarfatySBen AssayagEBovaIShopin L, Cohen M, Berliner S, Shapira I, BornsteinNM. Persistent hyperfibrinogenemia in acute ischemic stroke/transient ischemic attack (TIA). Thromb Haemost2008; 99: 169–173.
47.
YoussefMYZMojiminiyiOAAbdellaNA. Plasma concentrations of C-reactive protein and total homocysteine in relation to the severity and risk factors for cerebrovascular disease. Transl Res2007; 150: 158–163.
48.
VukasovicITesija-KunaATopicESupancVDemarinVPetrovcicM. Matrix metalloproteinases and their inhibitors in different acute stroke subtypes. Clin Chem Lab Med2006; 44: 428–434.
49.
Waje-AndreassenUKråkenesJUlvestadE, et al.IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand2005; 111: 360–365.
50.
TakanoKYamaguchiTKatoHOmaeT. Activation of coagulation in acute cardioembolic stroke. Stroke1991; 22: 12–16.
51.
AgenoWFinazziSSteidlL, et al.Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes. Arch Intern Med2002; 162: 2589–2593.
52.
CohenJFKorevaarDAAltmanDG, et al.STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open2016; 6: e012799.
53.
HasanNMcColganPBentleyPEdwardsRJSharmaP. Towards the identification of blood biomarkers for acute stroke in humans: a comprehensive systematic review. Br J Clin Pharmacol2012; 74: 230–240.
54.
MonbailliuTGoossensJHachimi-IdrissiS. Blood protein biomarkers as diagnostic tool for ischemic stroke: a systematic review. Biomark Med2017; 11: 503–512.
55.
MisraSKumarAKumarP, et al.Blood-based protein biomarkers for stroke differentiation: a systematic review. Proteomics Clin Appl2017; 11. 10.1002/prca.201700007.
56.
ZhangJZhangCHLinXLZhangQWangJShiSL. Serum glial fibrillary acidic protein as a biomarker for differentiating intracerebral hemorrhage and ischemic stroke in patients with symptoms of acute stroke: a systematic review and meta-analysis. Neurol Sci2013; 34: 1887–1892.
57.
SunYQinQShangYJ, et al.The accuracy of glial fibrillary acidic protein in acute stroke differential diagnosis: a meta-analysis. Scand J Clin Lab Invest2013; 73: 601–606.
58.
PerryLALucarelliTPenny-DimriJC, et al.Glial fibrillary acidic protein for the early diagnosis of intracerebral hemorrhage: systematic review and meta-analysis of diagnostic test accuracy. Int J Stroke2019; 14: 390–399.
59.
KumarAMisraSYadavAK, et al.Role of glial fibrillary acidic protein as a biomarker in differentiating intracerebral haemorrhage from ischaemic stroke and stroke mimics: a meta-analysis. Biomarkers2020; 25: 1–8.
60.
TakeshimaNSozuTTajikaAOgawaYHayasakaYFurukawaTA. Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference?. BMC Med Res Methodol2014; 14: 30.
61.
Ben AssayagEShenhar-TsarfatySOfekK, et al.Serum cholinesterase activities distinguish between stroke patients and controls and predict 12-month mortality. Mol Med2010; 16: 278–286.
62.
VanniSPolidoriGPepeG, et al.Use of biomarkers in triage of patients with suspected stroke. J Emerg Med2011; 40: 499–505.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
